Moreover, recent studies demonstrate that ADAR1 deletion reduces cancer cell viability via IFN-I pathway activation (24, 25), and in ADAR1-null tumors, there is a global reshaping of immune cell profiles, suggesting that inflammation caused by ADAR1 deletion can bypass the loss of tumor-specific CD8+ T cells (19, 26). This evidence concerns the gene ADAR and cancer.